Target Validation using Genomics and Informatics (Virtual)
Owing to the ongoing situation with covid-19, this event will be organised as a virtual conference.
In the past few years, exceptional progress has been made in making available thousands of DNA variants that are robustly associated with clinically relevant human traits. This is providing a rich source of molecular points for drug discovery and a deeper understanding of human biology.
This conference will highlight advances in the use of high-throughput methods and functional validation techniques that can influence the selection of new drug targets and the development of precision medicine. The programme will also explore the emerging technologies in drug discovery, including AI and machine learning. There will also be a focus on the challenges in clinical trials and translation into the clinic for the benefit of patients.
This meeting will bring together researchers based in academia, biotech and pharma to focus on the opportunities and challenges in using genomics and informatics in drug discovery and validation.
Topics will include:
- Genetics at scale
- Disease at scale
- Understanding and validation of target function
- Understanding and validation of drug function
- Translation into the clinic
- Emerging technologies for drug discovery
Wellcome Connecting Science
- Aviv Regev – Genentech, USA
- Carl Anderson – Wellcome Sanger Institute, UK
- Christoph Bock – CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
- Michael Boutros – German Cancer Research Center, Germany
- Daphne Koller – Insitro, USA
- Klio Maratou – GlaxoSmithKline, UK
- Ellie McDonagh – EMBL-EBI, UK
- Adele Mitchell – Biogen, USA
- Robert Plenge – Bristol Myers Squibb, USA
- James Sidaway – Apconix, UK
- Kari Stefansson – deCODE genetics, Iceland
- Cristen Willer – University of Michigan, USA
- Eleftheria Zeggini – Helmholtz Munich, Germany